Centauri Therapeutics Limited | Valuation, Funding Rounds & Stock Price | Caplight
Centauri Therapeutics Limited
Private
United Kingdom
Healthcare & Life Sciences Centauri Therapeutics Website
Last Round
Series A Extension
Feb 24, 2026
Total Funding Raised
$58.06M
Company Overview
Centauri Therapeutics Limited is a biotechnology company that develops novel immunotherapies for infectious diseases and oncology using its proprietary Alphamer platform technology.
Sector: Healthcare & Life Sciences
Verticals: Biotechnology, Drug Discovery
Business Model: B2B
Customer Profile: Services & Consulting, Data as a Service
AI Layer: Non-AI
Keywords: immunotherapy, antimicrobial resistance, AMR, drug discovery, bifunctional molecules, superbug treatment, antibody recruiting, biotech startup, oncology, infectious disease, preclinical development, drug pipeline, pharma licensing, biotech platform
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pricing Charts
Centauri Therapeutics Limited Comparables
Compare Centauri Therapeutics Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Clarametyx Biosciences | 79% | |
| Infex Therapeutics | 77% | |
| Aurobac Therapeutics | 76% | |
| Comparable company | 50% |
Centauri Therapeutics Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 24, 2026 | ||||
| Grant | Jul 29, 2025 | ||||
| Grant | Nov 25, 2024 | ||||
| Grant | Feb 22, 2022 | ||||
| Series A | Feb 16, 2022 | ||||
| Grant | Jan 7, 2020 |
Key People
Founding team and executive leadership
Samantha Macro
CFO
LinkedIn profile
Centauri Therapeutics Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series A Extension |
| Boehringer Ingelheim | Series A Extension, Series A |
| PACE (Pathways to Antimicrobial Clinical Efficacy) | Grant |
| CARB-X | Series A Extension, Grant |
| Innovate UK | Grant |
| Medicines Discovery Catapult | Grant |
| Novo Holdings | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
Jul 29, 2025
$5.1M grant from CARB-XJul 29, 2025
Developing ABX-01 programme, a broad-spectrum antimicrobial.
Centauri Therapeutics Limited Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
| Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Centauri Therapeutics Limited's valuation, stock price, and market status.
- Is Centauri Therapeutics Limited a public or private company?
- What is the current stock price of Centauri Therapeutics Limited?
- How much is Centauri Therapeutics Limited worth (valuation)?
- Can I buy Centauri Therapeutics Limited stock?
- When was Centauri Therapeutics Limited's last funding round?
- Who are the main investors in Centauri Therapeutics Limited?
- Will Centauri Therapeutics Limited IPO soon?
- How can I track Centauri Therapeutics Limited secondary market activity?
Firmographic Details
Headquarters: United Kingdom
Employee Range: 26
Year Founded: 2014
Last Funding: Feb 24, 2026